NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $75.31 +0.53 (+0.71 %) (As of 07/20/2018 04:00 PM ET)Previous Close$75.31Today's Range$74.10 - $75.3552-Week Range$62.56 - $93.14Volume720,955 shsAverage Volume1.37 million shsMarket Capitalization$11.52 billionP/E Ratio20.92Dividend YieldN/ABeta1 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York. Receive HSIC News and Ratings via Email Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical & hospital equipment Sub-IndustryHealth Care Distributors SectorMedical SymbolNASDAQ:HSIC CUSIP80640710 Webwww.henryschein.com Phone631-843-5500 Debt Debt-to-Equity Ratio0.34 Current Ratio1.44 Quick Ratio0.74 Price-To-Earnings Trailing P/E Ratio20.92 Forward P/E Ratio18.37 P/E Growth1.78 Sales & Book Value Annual Sales$12.46 billion Price / Sales0.93 Cash Flow$4.8966 per share Price / Cash15.38 Book Value$18.00 per share Price / Book4.18 Profitability EPS (Most Recent Fiscal Year)$3.60 Net Income$406.29 million Net Margins3.18% Return on Equity19.68% Return on Assets7.59% Miscellaneous Employees22,000 Outstanding Shares154,020,000Market Cap$11,517.99 Henry Schein (NASDAQ:HSIC) Frequently Asked Questions What is Henry Schein's stock symbol? Henry Schein trades on the NASDAQ under the ticker symbol "HSIC." When did Henry Schein's stock split? How did Henry Schein's stock split work? Henry Schein's stock split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split. How will Henry Schein's stock buyback program work? Henry Schein announced that its Board of Directors has authorized a share buyback plan on Tuesday, September 19th 2017, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 6.3% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued. How were Henry Schein's earnings last quarter? Henry Schein, Inc. (NASDAQ:HSIC) announced its earnings results on Tuesday, May, 8th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.03. The business had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.88 EPS. View Henry Schein's Earnings History. When is Henry Schein's next earnings date? Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Henry Schein. What guidance has Henry Schein issued on next quarter's earnings? Henry Schein issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.09. What price target have analysts set for HSIC? 19 equities research analysts have issued 1 year price targets for Henry Schein's shares. Their predictions range from $73.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $81.50 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Ratings for Henry Schein. What is the consensus analysts' recommendation for Henry Schein? 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Henry Schein stock? Here are some recent quotes from research analysts about Henry Schein stock: 1. According to Zacks Investment Research, "Post a better-than-expected first quarter performance on balanced segmental growth, we are impressed with Henry Schein's strong share gains in the North American and overseas markets. Despite the better-than-expected revenue performance in the last-reported quarter, we are disappointed with the year-over-year deterioration in Henry Schein's gross and operating margin due to higher costs and expenses. We currently await the completion of the company’s global Animal Health business' planned spin-off. This business contributes nearly 30% to the company’s topline. The spin off is expected to bring in major changes to Henry Schein’s overall operating results. On the flip side, pricing pressure and tough competition are major woes. Overall, in the past three months, Henry Schein has outperformed the broader industry." (7/14/2018) 2. Barrington Research analysts commented, "We are currently modeling $4.08. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur before year end. In addition, the guidance does not factor in any future M&A activity." (5/10/2018) Who are some of Henry Schein's key competitors? Some companies that are related to Henry Schein include Vertex Pharmaceuticals (VRTX), Illumina (ILMN), FRESENIUS SE &/S (FSNUY), Humana (HUM), Express Scripts (ESRX), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Edwards Lifesciences (EW), ESSILOR Intl S/S (ESLOY) and Fresenius Medical Care AG & Co. (FMS). Who are Henry Schein's key executives? Henry Schein's management team includes the folowing people: Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 68)Mr. James P. Breslawski, Vice Chairman & Pres (Age 64)Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 61)Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 65)Mr. Robert Minowitz, Sr. VP of Global Dental Merchandising & Bus. Operations (Age 59) Has Henry Schein been receiving favorable news coverage? News stories about HSIC stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Henry Schein earned a media sentiment score of 0.07 on Accern's scale. They also assigned news articles about the company an impact score of 45.33 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are Henry Schein's major shareholders? Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional investors include Swedbank (1.33%), Fenimore Asset Management Inc. (0.36%), Davis R M Inc. (0.30%), Riverbridge Partners LLC (0.27%), Bank of Montreal Can (0.24%) and Port Capital LLC (0.14%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein. Which major investors are selling Henry Schein stock? HSIC stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Swedbank, Bank of Montreal Can, Hartford Investment Management Co., Neville Rodie & Shaw Inc., Riverbridge Partners LLC, Gateway Investment Advisers LLC and Carderock Capital Management Inc.. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein. Which major investors are buying Henry Schein stock? HSIC stock was purchased by a variety of institutional investors in the last quarter, including Addenda Capital Inc., Xact Kapitalforvaltning AB, AMG National Trust Bank, Port Capital LLC, Addenda Capital Inc., State of Alaska Department of Revenue, Trust Co. of Oklahoma and DnB Asset Management AS. View Insider Buying and Selling for Henry Schein. How do I buy shares of Henry Schein? Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Henry Schein's stock price today? One share of HSIC stock can currently be purchased for approximately $75.31. How big of a company is Henry Schein? Henry Schein has a market capitalization of $11.52 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe. How can I contact Henry Schein? Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected] MarketBeat Community Rating for Henry Schein (NASDAQ HSIC)Community Ranking: 1.7 out of 5 ()Outperform Votes: 210 (Vote Outperform)Underperform Votes: 402 (Vote Underperform)Total Votes: 612MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?